Exosome Therapy for Parkinson's Disease

Exosome Therapy for Parkinson's Disease

Overview

Exosome Therapy for Parkinson's Disease

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Exosome Therapy for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">miRNA</td>
<td>Target</td>
</tr>
<tr>
<td class="label">miR-124</td>
<td>Neuroinflammation</td>
</tr>
<tr>
<td class="label">miR-7</td>
<td>Alpha-synuclein</td>
</tr>
<tr>
<td class="label">miR-153</td>
<td>Neuroprotection</td>
</tr>
<tr>
<td class="label">miR-29 family</td>
<td>Apoptosis</td>
</tr>
<tr>
<td class="label">miR-124-3p</td>
<td>Mitochondrial function</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Recommended Range</td>
</tr>
<tr>
<td class="label">Particle dose</td>
<td>1-10 × 10¹⁰ exosomes</td>
</tr>
<tr>
<td class="label">Volume per injection</td>
<td>50-200 muL</td>
</tr>
<tr>
<td class="label">Injection rate</td>
<td>0.5-2 muL/min</td>
</tr>
<tr>
<td class="label">Number of targets</td>
<td>2-4 per hemisphere</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">NCT05427080</td>
<td>Phase 1/2</td>
</tr>
<tr>
<td class="label">NCT05335304</td>
<td>Phase 1</td>
</tr>
<tr>
<td class="label">NCT04815625</td>
<td>Phase 2</td>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">NCT04388982</td>
<td>Phase 1</td>
</tr>
<tr>
<td class="label">NCT04919838</td>
<td>Phase 2</td>
</tr>
<tr>
<td class="label">NCT05558648</td>
<td>Phase 1</td>
</tr>
<tr>
<td class="label">Aspect</td>
<td>MSC Therapy</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Cell survival, immunomodulation, trophic support</td>
</tr>
<tr>
<td class="label">Tumor risk</td>
<td>Potential for abnormal proliferation</td>
</tr>
<tr>
<td class="label">Immune rejection</td>
<td>Allogeneic cells may be rejected</td>
</tr>
<tr>
<td class="label">Dosing</td>
<td>Limited cell expansion</td>
</tr>
<tr>
<td class="label">Storage</td>
<td>Cryopreservation challenges</td>
</tr>
<tr>
<td class="label">BBB penetration</td>
<td>Limited without modification</td>
</tr>
<tr>
<td class="label">Aspect</td>
<td>iPSC Neurons</td>
</tr>
<tr>
<td class="label">Integration</td>
<td>May integrate into circuitry</td>
</tr>
<tr>
<td class="label">Maturation</td>
<td>Variable differentiation</td>
</tr>
<tr>
<td class="label">Delivery</td>
<td>Surgical implantation</td>
</tr>
<tr>
<td class="label">Function</td>
<td>Replace lost neurons</td>
</tr>
<tr>
<td class="label">Timeline</td>
<td>Months for effects</td>
</tr>
<tr>
<td class="label">Aspect</td>
<td>AAV-GDNF/AAV-NTN</td>
</tr>
<tr>
<td class="label">Expression duration</td>
<td>Years (single dose)</td>
</tr>
<tr>
<td class="label">Reversibility</td>
<td>Not easily reversible</td>
</tr>
<tr>
<td class="label">Dosing control</td>
<td>Fixed expression</td>
</tr>
<tr>
<td class="label">Immune response</td>
<td>Viral capsid immunity</td>
</tr>
<tr>
<td class="label">Manufacturing</td>
<td>Complex viral production</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Method</td>
</tr>
<tr>
<td class="label">Particle size</td>
<td>NTA, DLS</td>
</tr>
<tr>
<td class="label">Particle concentration</td>
<td>NTA</td>
</tr>
<tr>
<td class="label">Marker expression</td>
<td>Flow cytometry</td>
</tr>
<tr>
<td class="label">Purity</td>
<td>Protein:particle ratio</td>
</tr>
<tr>
<td class="label">Sterility</td>
<td>Endotoxin, culture</td>
</tr>
<tr>
<td class="label">Identity</td>
<td>Cargo quantification</td>
</tr>
</table>

Exosome therapy for Parkinson's disease (PD) represents a cutting-edge approach that leverages extracellular vesicles (EVs) as natural delivery vehicles for therapeutic cargo to the brain. These nanoscale vesicles (30-150 nm) are secreted by various cell types and can cross the [blood-brain barrier](/entities/blood-brain-barrier), making them attractive carriers for delivering neuroprotective and restorative proteins to dopaminergic [neurons](/entities/neurons) in the [substantia nigra](/mechanisms/parkinsons-disease-selective-substantia-nigra-vulnerability).[@deng2019]

While general exosome therapy pages exist, PD-specific applications require detailed coverage of cargo options (GDNF, CDNF, microRNAs, siRNA), delivery methods optimized for deep brain structures, and direct comparison to cell therapy approaches. This page consolidates the current state of exosome-based therapeutics specifically for Parkinson's disease treatment.

Exosome Biology and Parkinson's Disease Relevance

Pathophysiological Rationale

Parkinson's disease is characterized by progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to motor symptoms (tremor, bradykinesia, rigidity) and non-motor symptoms (sleep disorders, autonomic dysfunction, cognitive decline). The pathological hallmarks include:

• Lewy bodies: Intracellular inclusions composed primarily of misfolded [alpha-synuclein](/proteins/alpha-synuclein) aggregates
• Lewy neurites: Degenerative neurites containing phosphorylated tau and alpha-synuclein
• Neuroinflammation: Chronic activation of microglia contributing to neuronal loss
• Mitochondrial dysfunction: Impaired energy metabolism and increased oxidative stress

Exosome-Mediated Alpha-Synuclein Propagation

Endogenous exosomes from neurons and glial cells can contain and transfer pathological alpha-synuclein between brain regions, contributing to disease progression. However, this same mechanism can be exploited:

Neuroinflammation Modulation

PD-associated neuroinflammation involves persistent activation of microglia and astrocytes. MSC-derived exosomes contain anti-inflammatory molecules that can:

• Suppress pro-inflammatory cytokine production (IL-1β, TNF-α, IL-6)
• Promote anti-inflammatory cytokine secretion (IL-10, TGF-β)
• Modulate microglial phenotype from M1 (pro-inflammatory) to M2 (protective)
• Reduce astrogliosis and preserve neuronal microenvironment[@drommelschmidt2017]

Therapeutic Cargo Options

GDNF (Glial Cell Line-Derived Neurotrophic Factor)

GDNF is one of the most potent neurotrophic factors for dopaminergic neurons, promoting their survival, function, and regeneration. Delivery via exosomes addresses historical challenges with direct GDNF infusion.

Mechanism of Action:

• Binds to GFRα1 receptor on dopaminergic neurons
• Activates RET tyrosine kinase signaling
• Triggers PI3K/Akt (cell survival), MAPK/ERK (differentiation), and PLCγ (calcium signaling) pathways

• Sustained release of GDNF from exosome cargo
• Enhanced BBB penetration compared to direct protein delivery
• Reduced immunogenicity compared to viral gene therapy
• Tunable dosing through repeat administration

• MSC-derived exosomes loaded with GDNF show enhanced dopaminergic neuron protection in MPTP mouse models
• Combination of MSC exosomes with GDNF overexpression shows synergistic effects in vitro[@yong2019]

CDNF (Cerebral Dopamine Neurotrophic Factor)

CDNF is a neurotrophic factor with high affinity for dopaminergic neurons and distinct mechanism from GDNF. It provides neuroprotection through:

• Endoplasmic reticulum stress reduction
• Unfolded protein response modulation
• Autophagy enhancement
• Direct dopaminergic neuron protection

• CDNF-loaded exosomes show promise in 6-OHDA rat models of PD
• Combination with MSC-derived exosomes provides additional anti-inflammatory benefits
• Superior to direct CDNF infusion in terms of distribution and sustained release[@voutilainen2015]

• [CDNF Therapy for Parkinson's Disease](/therapeutics/cdnf-therapy-parkinsons) page covers human trials
• Phase 1/2 trials ongoing with intraparenchymal delivery
• Exosome-encapsulated CDNF remains at preclinical stage

microRNAs (miRNAs)

MicroRNAs delivered via exosomes can modulate gene expression in recipient neurons to promote survival and function.

Key miRNAs for PD:

Loading Methods:

• Endogenous loading through cellular overexpression
• Electroporation for siRNA/miRNA loading
• Lipid-mediated transfection
• Exosome surface display of miRNA "sponges"[@kojima2018]

siRNA (Small Interfering RNA)

siRNA can be used to knock down expression of genes that contribute to PD pathogenesis:

• SNCA: Reduce alpha-synuclein production
• LRRK2: Target gain-of-function mutations (G2019S)
• GBA: Reduce glucocerebrosidase-related pathology
• Parkin/PINK1: Enhance mitophagy in damaged neurons

• siRNA requires efficient loading into exosomes
• Chemical modifications enhance stability
• Targeting ligands improve delivery to specific cell types
• Combination with neurotrophic factors provides synergistic benefits

Delivery Methods

Systemic Administration

Intravenous (IV) Delivery:

• Most common route for clinical translation
• Requires targeting modifications for brain delivery
• Surface engineering with brain-targeting ligands (rabies virus glycoprotein peptide, angiopep-2)
• Dose: Typically 1-10 × 10¹⁰ particles per kg

• Direct nose-to-brain pathway bypasses BBB
• Faster onset of action
• Lower systemic exposure
• Suitable for repeated dosing
• [Exosome Delivery via Nasal Route](/ideas/delivery-exosome-nasal) page covers details

Direct Brain Delivery

Intraparenchymal Injection:

• Stereotactic injection to substantia nigra/putamen
• Higher local concentrations achievable
• Requires surgical procedure
• Used in clinical trials (NCT05427080)

• Injection into cerebrospinal fluid
• Distributes throughout CNS
• Useful for reaching multiple brain regions
• Requires repeated administrations

Optimized Approaches for PD

Targeted Substantia Nigra Delivery:

• Stereotactic targeting using MRI guidance
• Bilateral injection often required
• CED (convection-enhanced delivery) improves distribution
• Real-time imaging for verification

Clinical Trials Status

Active and Recruiting Trials

Completed Trials

Emerging Trials (2026)

• First-in-human trials of exosome-encapsulated GDNF for PD expected
• iPSC-derived exosomes with neurotrophic cargo entering clinical testing
• Targeted exosomes with brain-penetrating peptides in preclinical development[@matsumoto2020]

Biomarkers for Treatment Response

Neuroimaging:

• DaTscan (dopamine transporter imaging)
• PET with FDG (glucose metabolism)
• MRI with neuromelanin imaging

• Neurofilament light chain (NfL) in CSF/serum
• Alpha-synuclein seeding assays
• Inflammatory cytokines (IL-6, TNF-α)
• Neurotrophic factor levels (BDNF, GDNF)

Comparison to Cell Therapy Approaches

Mesenchymal Stem Cell (MSC) Therapy

iPSC-Derived Dopaminergic Neuron Therapy

Direct Viral Gene Therapy

Hybrid Approaches

Exosome-Producing Cells:

• Genetically engineered cells that secrete therapeutic exosomes
• Can be implanted (cell therapy + exosome hybrid)
• Provides sustained exosome release in vivo
• Example: GDNF-secreting MSCs

• Combine MSC transplantation with exosome co-administration
• MSC provide local signaling, exosomes deliver specific cargo
• Synergistic neuroprotection

Manufacturing and Quality Control

Exosome Production

• Umbilical cord-derived MSCs (UC-MSCs)
• Bone marrow-derived MSCs
• iPSC-derived mesenchymal cells
• Engineered cell lines

• Traditional 2D culture (scalability limited)
• 3D bioreactor systems (enhanced yield)
• Hollow fiber bioreactors (clinical scale)

• Ultracentrifugation (gold standard)
• Size-exclusion chromatography
• Tangential flow filtration
• Immunoaffinity capture

Characterization Requirements

Regulatory Considerations

• FDA guidance for cell-derived extracellular vesicles in development
• EMA has specific guidelines for ATMPs (Advanced Therapy Medicinal Products)
• Exosomes classified as biological product with specific CMC requirements
• IND-enabling studies require GMP-grade manufacturing

Challenges and Future Directions

Current Challenges

• Optimize loading methods for different cargo types
• Maintain cargo integrity during loading
• Achieve therapeutic dosing

• Enhance brain targeting while reducing off-target
• Achieve substantia nigra-specific delivery
• Reduce peripheral organ accumulation

• Establish optimal dose and frequency
• Determine treatment duration
• Identify biomarkers for response

• Consistent lot-to-lot production
• Cost-effective manufacturing
• Quality control at scale

Emerging Innovations

• Brain-penetrating exosomes: Engineered with novel peptides for enhanced BBB crossing
• Stimulus-responsive exosomes: Activated by specific brain conditions
• Theranostic exosomes: Combined therapeutic and diagnostic functions
• Personalized exosomes: Patient-derived cells for individualized therapy
• Gene-edited exosomes: CRISPR cargo for precise genetic modulation

See Also

• [Exosome Therapy for Neurodegeneration](/therapeutics/exosome-therapy)
• [GDNF Therapy for Parkinson's Disease](/therapeutics/gdnf-therapy-parkinsons)
• [CDNF Therapy for Parkinson's Disease](/therapeutics/cdnf-therapy-parkinsons)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Dopaminergic Neurons](/cell-types/dopaminergic-neurons)
• [Alpha-Synuclein](/proteins/alpha-synuclein)
• [Exosome Biogenesis](/mechanisms/exosome-biogenesis)
• [Neuroinflammation in PD](/mechanisms/neuroinflammation)

External Links

• [ClinicalTrials.gov - Exosome Parkinson's](https://clinicaltrials.gov)
• [ISEV Guidelines for Extracellular Vesicle Research](https://www.isev.org/)
• [Michael J. Fox Foundation - Therapeutic Strategies](https://www.michaeljfox.org/)
• [Parkinson's Foundation - Research Updates](https://www.parkinson.org/)

References